Billions of dollars of debt incoming as Allergan shareholders agree takeover

By Mike Turner
17 Oct 2019

Allergan shareholders have waved through its acquisition by rival drug company AbbVie, clearing a major hurdle on the way to billions of dollars of loans and an expected $30bn of bond issuance.

Votes representing around 68.6% of outstanding shares in US pharmaceuticals company Allergan were cast at an extraordinary general meeting this week, with the overwhelming majority of those — more than 99% — in favour of the acquisition. 

“This combination will create a leading biopharmaceutical company with a diversified portfolio ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access:

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: or find out more online here.